Understanding how S100A4 affects immune suppression in brain tumors
S100A4 mediated immune suppression in GBM
This study is looking at how a protein called S100A4 affects the way glioblastoma, a tough type of brain tumor, interacts with the immune system, with the goal of finding new ways to improve treatment for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11015037 on NIH RePORTER |
What this research studies
This research investigates the role of S100A4, a calcium-binding protein, in the immune suppression associated with glioblastoma (GBM), an aggressive brain tumor. The study aims to uncover how S100A4 influences the interactions between glioma cells and immune cells, which may hinder the effectiveness of immunotherapy. By analyzing single-cell RNA sequencing data and correlating S100A4 expression with patient survival and immune markers, the researchers hope to identify new therapeutic targets that could enhance treatment outcomes for GBM patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking new treatment options.
Not a fit: Patients with non-glioblastoma brain tumors or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for patients with glioblastoma, potentially increasing survival rates.
How similar studies have performed: Previous research has shown promise in targeting immune suppression in glioblastoma, but the specific role of S100A4 in this context is still being explored.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Yun, Kyuson — Methodist Hospital Research Institute
- Study coordinator: Yun, Kyuson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.